Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2000-07-27
2002-03-12
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S406000, C514S471000, C514S479000, C514S492000
Reexamination Certificate
active
06355628
ABSTRACT:
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to combinations of pentafluorobenzenesulfonamides and cisplatin that are capable of inhibiting abnormal cell proliferation.
BACKGROUND
Cancer is a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body. A multitude of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer. The most commonly used types of anticancer agents include: DNA-alkylating agents (e.g., cyclophosphamide, ifosfamide), antimetabolites (e.g., methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist), microtubule disrupters (e.g., vincristine, vinblastine, paclitaxel), DNA intercalators (e.g., doxorubicin, daunomycin, cisplatin), and hormone therapy (e.g., tamoxifen, flutamide). The ideal antineoplastic drug would kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells. It would also retain its efficacy against malignant cells, even after prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess an ideal profile. Most possess very narrow therapeutic indexes and, in practically every instance, cancerous cells exposed to slightly sublethal concentrations of a chemotherapeutic agent will develop resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents.
The development of new anticancer agents has given rise to new treatment regimens and new combinations that are proving more effective in combating this disease.
Accordingly, it is one object of the present invention to provide compositions which directly or indirectly are toxic to actively dividing cells and are useful in the treatment of cancer.
A further object of the present invention is to provide methods for killing actively proliferating cells, such as cancerous, bacterial, or epithelial cells, and treating all types of cancers, and generally proliferative conditions. A further object is to provide methods for treating other medical conditions characterized by the presence of rapidly proliferating cells, such as psoriasis and other skin disorders.
Additional objects, features and advantages will become apparent to those skilled in the art from the following description and claims.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides compositions useful for the treatment of cancer and other diseases associated with abnormal cell proliferation. The compositions comprise cisplatin (or a related platinum coordination complex, e.g., carboplatin) and a compound having the formula:
In the formula above, the letter R represents a hydrogen, substituted or unsubstituted (C
1
-C
10
)alkyl, or substituted or unsubstituted (C
3
-C
6
)alkenyl. The symbol Ar represents a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
In another aspect, the present invention provides methods for the treatment of cancer and other proliferative disorders using the compositions provided above.
REFERENCES:
patent: 1955207 (1934-04-01), Stotter et al.
patent: 2402623 (1946-06-01), Hester et al.
patent: 3034955 (1962-05-01), Frick et al.
patent: 4881969 (1989-11-01), Saupe et al.
patent: 4883914 (1989-11-01), Alvarado et al.
patent: 4900867 (1990-02-01), Wilkes et al.
patent: 5250549 (1993-10-01), Yoshino et al.
patent: 5385931 (1995-01-01), Bigg et al.
patent: 5387709 (1995-02-01), Lardy et al.
patent: 5773236 (1998-06-01), Diwu et al.
patent: 5880151 (1999-03-01), Medina et al.
patent: 5891917 (1999-04-01), Tange et al.
patent: 0 469 901 (1992-02-01), None
patent: WO 97/30677 (1994-04-01), None
patent: 1242057 (1971-08-01), None
patent: 1306564 (1973-02-01), None
Fielding, et al.; “Synthesis and reactions of 4-sulpho-2,3,5,6,-tetrafluorobenzoic acid”,Journal of Fluorine Chemistry, Oct. 1992, Vol. 59, No. 1, pp. 15-31.
Raibekas, et al.; “Affinity Probing of Flavin Binding Sites. 2. Identification of a Reactive Cysteine in the Flavin Domain ofEscherichia coliDNA Photolyase”;Biochemistry1994, vol. 33, No. 42, pp. 12656-12664.
Shealy, et al.; “2-Haloethylating Agents for Cancer Chemotherapy. 2-Haloethyl Sulfonates”;Journal of Medicinal Chemistry, Aug. 1983, vol. 26, No. 8, pp. 1168-1173.
Olander, et al.; “A Study of the Binding of Two Sulfonamides to Carbonic Anhydrase”;Journal of the American Chemical Society, Mar. 1973, vol. 95, No. 5, pp. 1616-1621.
Hawkinson, et al.; “Studies of the Solvolysis of 2-Adamantyl Pentafluorobenzenesulfonate: A YPFBSScale1”;The Journal of Organic Chemistry, Aug., 1988, vol. 53, No. 16, pp. 3857-3860.
Bai, et al.; “Identification of the Cysteine Residue of &bgr;-Tubulin Alkylated by the Antimitotic Agent 2,4-Dichlorobenzyl Thiocyanate, Facilitated by Separation of the Protein Subunits of Tubulin by Hydrophobic Column Chromatography”;Biochemisty1989, vol. 28, pp. 5606-5612.
Fadeeva, V.P., “Gas-chromatography separation of sulfur-and fluorine-containing pyrolysis products”,Chemical Abstracts, 76:(5) (Jan. 31, 1972).
Gerig et al., “Aromatic Rign Dynamics in a Carbonic Anhydrase-Inhibitor Complex”,Journal of the Chemical Society Chemical Communications, No. 6, pp 482-484 (1987).
Luduena, E.F., et al. Interaction of Ethacrynic Acid with Bovine Brain Tubulin,Biochemical Pharmacology, 47:(9) 1677-1681 (Apr. 29, 1994).
March, Advanced Organic Chemistry, 4th Edition, 1992 p. 497.
Yoshimoto et al., “Correlation Analysis of Baker's Studios . . . ”, J. Med. Chem, 19:(1) 71-98 (1976).
Schwendner Susan
Timmermans Pieter
Walling Jacqueline
O'Sullivan Peter
Townsend and Townsend / and Crew LLP
Tularik Inc.
LandOfFree
Combination therapy using pentafluorobenzenesulfonamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using pentafluorobenzenesulfonamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using pentafluorobenzenesulfonamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2827898